Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00168129|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : December 9, 2011
|Condition or disease||Intervention/treatment||Phase|
|Bone Neoplasms||Procedure: Helical tomotherapy||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases|
|Study Start Date :||June 2001|
|Study Completion Date :||July 2005|
- To deliver a single fraction of radiotherapy safely to patients with bone metastases using helical tomotherapy
- To assess and quantify the acute toxicity of patients with bone metastases treated with helical tomotherapy.
- To measure invivo dosimetry and compare delivered doses to computer-reconstructed dose distribution.
- To determine the maximum tolerated does of palliative radiation give with helical tomotherapy in a single fraction.
- To assess the efficacy (pain control) of radiotherapy given with helical tomotherapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168129
|Cross Cancer Institute|
|Edmonton, Alberta, Canada|
|Principal Investigator:||Rufus Scrimger, MD||AHS Cancer Control Alberta|